Clin Exp Vaccine Res.  2018 Jan;7(1):37-42. 10.7774/cevr.2018.7.1.37.

Anti-infective potential of catechins and their derivatives against viral hepatitis

• Song JM

• KMID: 2402536
• DOI: http://doi.org/10.7774/cevr.2018.7.1.37

Abstract

Polyphenols including catechins from green tea (Camellia sinensis) have been reported to have anti-infective activities against a broad spectrum of viruses and other pathogens. During the last two decades, antiviral activities of catechins with different modes of action have been demonstrated on diverse families of viruses, such as human immunodeficiency virus, Herpes simplex virus, influenza virus, hepatitis B and C virus. In this study, we focused on the antiviral properties of catechins and their derivatives against viral hepatitis which have become a key public health issue due to their serious impact on human health with liver diseases.

Keyword

Catechin; Hepatitis; Antiviral agents

MeSH Terms

Antiviral Agents
Catechin*
Hepatitis B
Hepatitis*
HIV
Humans
Liver Diseases
Orthomyxoviridae
Polyphenols
Public Health
Simplexvirus
Tea
Antiviral Agents
Catechin
Polyphenols
Tea

Figure

• 

  Fig. 1 Schematic diagram of catechins. EC, epicatechin; EGC, epigallocatechin; ECG, epicatechin-gallate; EGCG, epigallocatecin 3-gallate.

Reference

1. Cao J, Han J, Xiao H, Qiao J, Han M. Effect of tea polyphenol compounds on anticancer drugs in terms of anti-tumor activity, toxicology, and pharmacokinetics. Nutrients. 2016; 8:E762. PMID: 27983622.

2. Nakayama M, Suzuki K, Toda M, Okubo S, Hara Y, Shimamura T. Inhibition of the infectivity of influenza virus by tea polyphenols. Antiviral Res. 1993; 21:289–299. PMID: 8215301.

3. Kim M, Kim SY, Lee HW, et al. Inhibition of influenza virus internalization by (−)-epigallocatechin-3-gallate. Antiviral Res. 2013; 100:460–472. PMID: 23954192.

4. Song JM, Lee KH, Seong BL. Antiviral effect of catechins in green tea on influenza virus. Antiviral Res. 2005; 68:66–66. PMID: 16137775.

5. Yamaguchi K, Honda M, Ikigai H, Hara Y, Shimamura T. Inhibitory effects of (−)-epigallocatechin gallate on the life cycle of human immunodeficiency virus type 1 (HIV-1). Antiviral Res. 2002; 53:19–34. PMID: 11684313.

6. Fassina G, Buffa A, Benelli R, Varnier OE, Noonan DM, Albini A. Polyphenolic antioxidant (−)-epigallocatechin-3-gallate from green tea as a candidate anti-HIV agent. AIDS. 2002; 16:939–941. PMID: 11919502.

7. Williamson MP, McCormick TG, Nance CL, Shearer WT. Epigallocatechin gallate, the main polyphenol in green tea, binds to the T-cell receptor, CD4: potential for HIV-1 therapy. J Allergy Clin Immunol. 2006; 118:1369–1374. PMID: 17157668.

8. Weber C, Sliva K, von Rhein C, Kummerer BM, Schnierle BS. The green tea catechin, epigallocatechin gallate inhibits chikungunya virus infection. Antiviral Res. 2015; 113:1–3. PMID: 25446334.

9. Lyu SY, Rhim JY, Park WB. Antiherpetic activities of flavonoids against herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) in vitro. Arch Pharm Res. 2005; 28:1293–1301. PMID: 16350858.

10. Isaacs CE, Wen GY, Xu W, et al. Epigallocatechin gallate inactivates clinical isolates of herpes simplex virus. Antimicrob Agents Chemother. 2008; 52:962–970. PMID: 18195068.

11. Isaacs CE, Xu W, Merz G, Hillier S, Rohan L, Wen GY. Digallate dimers of (−)-epigallocatechin gallate inactivate herpes simplex virus. Antimicrob Agents Chemother. 2011; 55:5646–5653. PMID: 21947401.

12. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005; 5:558–558. PMID: 16122679.

13. Kenny-Walsh E. The natural history of hepatitis C virus infection. Clin Liver Dis. 2001; 5:969–977. PMID: 11685804.

14. Alter MJ. Epidemiology of hepatitis C. Hepatology. 1997; 26(3 Suppl 1):62S–65S. PMID: 9305666.

15. Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut. 2006; 55:1350–1359. PMID: 16905701.

16. Chen C, Qiu H, Gong J, et al. (−)-Epigallocatechin-3-gallate inhibits the replication cycle of hepatitis C virus. Arch Virol. 2012; 157:1301–1312. PMID: 22491814.

17. Fukazawa H, Suzuki T, Wakita T, Murakami Y. A cell-based, microplate colorimetric screen identifies 7,8-benzoflavone and green tea gallate catechins as inhibitors of the hepatitis C virus. Biol Pharm Bull. 2012; 35:1320–1327. PMID: 22863932.

18. Rivero-Buceta E, Carrero P, Doyaguez EG, et al. Linear and branched alkyl-esters and amides of gallic acid and other (mono-, di- and tri-) hydroxy benzoyl derivatives as promising anti-HCV inhibitors. Eur J Med Chem. 2015; 92:656–671. PMID: 25617695.

19. Xu J, Wang J, Deng F, Hu Z, Wang H. Green tea extract and its major component epigallocatechin gallate inhibits hepatitis B virus in vitro. Antiviral Res. 2008; 78:242–249. PMID: 18313149.

20. Ye P, Zhang S, Zhao L, et al. Tea polyphenols exerts antihepatitis B virus effects in a stably HBV-transfected cell line. J Huazhong Univ Sci Technolog Med Sci. 2009; 29:169–169. PMID: 19399398.

21. He W, Li LX, Liao QJ, Liu CL, Chen XL. Epigallocatechin gallate inhibits HBV DNA synthesis in a viral replicationinducible cell line. World J Gastroenterol. 2011; 17:1507–1514. PMID: 21472112.

22. Ciesek S, von Hahn T, Colpitts CC, et al. The green tea polyphenol, epigallocatechin-3-gallate, inhibits hepatitis C virus entry. Hepatology. 2011; 54:1947–1955. PMID: 21837753.

23. Calland N, Albecka A, Belouzard S, et al. (−)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry. Hepatology. 2012; 55:720–729. PMID: 22105803.

24. Calland N, Sahuc ME, Belouzard S, et al. Polyphenols inhibit hepatitis C virus entry by a new mechanism of action. J Virol. 2015; 89:10053–10063. PMID: 26202241.

25. Colpitts CC, Schang LM. A small molecule inhibits virion attachment to heparan sulfate- or sialic acid-containing glycans. J Virol. 2014; 88:7806–7817. PMID: 24789779.

26. Wang Y, Li J, Wang X, et al. (−)-Epigallocatechin-3-gallate enhances hepatitis C virus double-stranded RNA intermediates-triggered innate immune responses in hepatocytes. Sci Rep. 2016; 6:21595. PMID: 26879672.

27. Wong J, Zhang J, Si X, et al. Autophagosome supports coxsackievirus B3 replication in host cells. J Virol. 2008; 82:9143–9143. PMID: 18596087.

28. Li J, Liu Y, Wang Z, et al. Subversion of cellular autophagy machinery by hepatitis B virus for viral envelopment. J Virol. 2011; 85:6319–6333. PMID: 21507968.

29. Sir D, Kuo CF, Tian Y, et al. Replication of hepatitis C virus RNA on autophagosomal membranes. J Biol Chem. 2012; 287:18036–18043. PMID: 22496373.

30. Tanida I. Autophagy basics. Microbiol Immunol. 2011; 55:1–11. PMID: 21175768.

31. Zhong L, Hu J, Shu W, Gao B, Xiong S. Epigallocatechin-3-gallate opposes HBV-induced incomplete autophagy by enhancing lysosomal acidification, which is unfavorable for HBV replication. Cell Death Dis. 2015; 6:e1770. PMID: 25996297.

32. Liao PC, Ng LT, Lin LT, Richardson CD, Wang GH, Lin CC. Resveratrol arrests cell cycle and induces apoptosis in human hepatocellular carcinoma Huh-7 cells. J Med Food. 2010; 13:1415–1423. PMID: 20946021.

33. Mekky RY, El-Ekiaby NM, Hamza MT, et al. Mir-194 is a hepatocyte gate keeper hindering HCV entry through targeting CD81 receptor. J Infect. 2015; 70:78–87. PMID: 25218426.

34. Lee JC, Tseng CK, Wu SF, Chang FR, Chiu CC, Wu YC. San-Huang-Xie-Xin-Tang extract suppresses hepatitis C virus replication and virus-induced cyclooxygenase-2 expression. J Viral Hepat. 2011; 18:e315–e324. PMID: 21692943.

35. Lu L, Wei L, Peng G, et al. NS3 protein of hepatitis C virus regulates cyclooxygenase-2 expression through multiple signaling pathways. Virology. 2008; 371:61–70. PMID: 17964630.

36. Nunez O, Fernandez-Martinez A, Majano PL, et al. Increased intrahepatic cyclooxygenase 2, matrix metalloproteinase 2, and matrix metalloproteinase 9 expression is associated with progressive liver disease in chronic hepatitis C virus infection: role of viral core and NS5A proteins. Gut. 2004; 53:1665–1672. PMID: 15479690.

37. Giannitrapani L, Ingrao S, Soresi M, et al. Cyclooxygenase-2 expression in chronic liver diseases and hepatocellular carcinoma: an immunohistochemical study. Ann N Y Acad Sci. 2009; 1155:293–299. PMID: 19250220.

38. Roh C, Jo SK. (−)-Epigallocatechin gallate inhibits hepatitis C virus (HCV) viral protein NS5B. Talanta. 2011; 85:2639–2639. PMID: 21962695.

39. Fatima K, Mathew S, Suhail M, et al. Docking studies of Pakistani HCV NS3 helicase: a possible antiviral drug target. PLoS One. 2014; 9:e106339. PMID: 25188400.

40. Huang HC, Chen CC, Chang WC, Tao MH, Huang C. Entry of hepatitis B virus into immortalized human primary hepatocytes by clathrin-dependent endocytosis. J Virol. 2012; 86:9443–9453. PMID: 22740403.

41. Huang HC, Tao MH, Hung TM, Chen JC, Lin ZJ, Huang C. (−)-Epigallocatechin-3-gallate inhibits entry of hepatitis B virus into hepatocytes. Antiviral Res. 2014; 111:100–111. PMID: 25260897.